Targeted Therapy
Approved for: NSCLC
EGFR
Afatinib (Gilotrif) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body).
It is used: As first-line treatment in patients with tumors that have certain EGFR gene mutations.
